معرفی
Naohiro Okada is an Associate Professor at the Graduate School of Medicine, Department of Psychiatry, The University of Tokyo, and concurrently serves as an Associate Professor at the International Research Center for Neurointelligence (IRCN). He is also the Core Manager of the Human fMRI Core facility. Dr. Okada has extensive experience in neuroimaging research, particularly focusing on psychiatric disorders and adolescent brain development.
Dr. Okada obtained his M.D. from the University of Tokyo Faculty of Medicine in 2004. After completing his residency, he began psychiatry training at the University of Tokyo Hospital in 2006 and worked as a psychiatrist at Tokyo Metropolitan Matsuzawa Hospital from 2007 to 2012. He earned his Ph.D. from the Graduate School of Medicine, University of Tokyo in 2017, and joined IRCN in 2019 where he manages the human fMRI scanner facility.
His research primarily focuses on using functional magnetic resonance imaging (fMRI) to understand brain structure and function in healthy adolescents and patients with psychiatric disorders. Dr. Okada's work aims to elucidate the neurobiological substrates of psychiatric disorders and develop biomarkers for clinical applications. He has published extensively on topics including schizophrenia, autism spectrum disorder, depression, and adolescent brain development, with a particular emphasis on multi-site collaborative studies and data-driven approaches to psychiatric classification.
Dr. Okada's recent publications demonstrate a strong focus on developing novel diagnostic classifications based on neuroimaging data, investigating resting-state neural signatures across psychiatric disorders, and establishing robust infrastructure for multi-center MRI research. His work bridges human and animal research while incorporating machine learning and AI techniques to advance the field of psychiatric neuroimaging.
Dr. Okada is actively involved in several research projects funded by the Japan Society for the Promotion of Science, including the Advanced Bioimaging Support Platform (2022-2028), MRS analysis of basal ganglia GABA dysfunction in schizophrenia (2021-2025), and studies on dose reduction and brain function changes in schizophrenia patients (2018-2022).
He is a member of the Society for Neuroscience and the Japanese Society of Biological Psychiatry, reflecting his commitment to advancing neuroscience research and its applications in understanding and treating psychiatric disorders.
